UOC
KDNY

UBS O'Connor’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

UBS O'Connor’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-15,000
Closed -$562K – 404
2017
Q4 		$562K Buy
+15,000
New +$655K 0.01% 261

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS O'Connor's KDNY Position: Q1 2018 in Review

UBS O'Connor sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2018, closing a stake of 15,000 shares — an estimated $562K sold.

UBS O'Connor first reported a position in KDNY in Q4 2017 and held it in 1 quarter. The position peaked at $562K in Q4 2017. 92 funds tracked by Wall St. Rank hold KDNY as of Q1 2018.

  • UBS O'Connor reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • UBS O'Connor sold 15,000 Chinook Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $562K.
  • UBS O'Connor first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • UBS O'Connor's Chinook Therapeutics, Inc. Common Stock position peaked at $562K in Q4 2017.
  • 92 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2018.

Based on UBS O'Connor's 13F filing for Q1 2018, filed 14 May 2018.